[EN] ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS ANTIBACTÉRIENS ET LEURS PROCÉDÉS D'UTILISATION
申请人:UNIV NOTRE DAME DU LAC
公开号:WO2009041972A1
公开(公告)日:2009-04-02
Embodiments of the present invention provide novel antibactehals that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, such as certain strains of Entercoccus and Staphylococcus aureus.
Embodiments of the present invention provide novel antibacterials that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, such as certain strains of
Entercoccus
and
Staphylococcus aureus.
Discovery of a New Class of Non-β-lactam Inhibitors of Penicillin-Binding Proteins with Gram-Positive Antibacterial Activity
作者:Peter I. O’Daniel、Zhihong Peng、Hualiang Pi、Sebastian A. Testero、Derong Ding、Edward Spink、Erika Leemans、Marc A. Boudreau、Takao Yamaguchi、Valerie A. Schroeder、William R. Wolter、Leticia I. Llarrull、Wei Song、Elena Lastochkin、Malika Kumarasiri、Nuno T. Antunes、Mana Espahbodi、Katerina Lichtenwalter、Mark A. Suckow、Sergei Vakulenko、Shahriar Mobashery、Mayland Chang
DOI:10.1021/ja500053x
日期:2014.3.5
Infections caused by hard-to-treat methicillin-resistant Staphylococcus aureus (MRSA) are a serious global public-health concern, as MRSA has become broadly resistant to many classes of antibiotics. We disclose herein the discovery of a new class of non-beta-lactam antibiotics, the oxadiazoles, which inhibit penicillin-binding protein 2a (PBP2a) of MRSA. The oxadiazoles show bactericidal activity against vancomycin-and linezolid-resistant MRSA and other Gram-positive bacterial strains, in vivo efficacy in a mouse model of infection, and have 100% oral bioavailability.